Welcome back to Endpoints Weekly! Our team tracked a handful of deals announced this week as the first quarter comes to a close. Check below
Otsuka is buying neuropsychiatric drugmaker Transcend Therapeutics in a deal worth roughly $1.2 billion, further bolstering a class of drugs that are supposed to provide
The European Medicines Agency’s human medicines committee has recommended the approval of four new drugs and a new form of Sanofi’s multiple myeloma drug. CHMP
Plus, news about Zenas and Ysios Capital: 🌀 AnaptysBio’s spinout: The independent public company, called First Tracks Biotherapeutics, is expected to start trading on April
A rare disease gene therapy from Rocket Pharmaceuticals has garnered FDA approval after an earlier rejection for manufacturing problems. The FDA on Thursday granted accelerated
Shionogi is doubling down on its sleep disorder pipeline by buying out Apnimed’s half of their joint venture in the niche field.
The Japanese pharma will pay $100 million upfront to buy the 50% equity …
Copyright 2025 dijee Intelligence Ltd. dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844